Medtronic Reports the Completion of Patient Enrollment of Pulsed Field Ablation Catheter in (SPHERE Per-AF) Trial for the Treatment of Atrial Fibrillation
Shots:
- The company has completed the patient enrolment in the (SPHERE Per-AF) trial evaluating Sphere-9 pulsed field (PF) in 477 patients with persistent AF across 23 centers in the US & EU. Patients will now be followed for 12mos.
- Sphere-9 catheter can deliver both RF & PF energies for ablation, combining mapping, navigation & therapeutic capabilities providing users with more options when performing ablation procedures
- The study focuses to determine the safety and effectiveness of Sphere-9 cardiac ablation and mapping catheter with the Affera cardiac mapping and navigation platform & improve efficiencies by enabling intuitive HD mapping to diagnose arrhythmias with a single catheter
Ref: Medtronic | Image: Medtronic
Click here to read the full press release